Gastrointestinal stromal tumours in patients presenting to an academic hospital in South Africa

SA Journal of Oncology

Field Value
Title Gastrointestinal stromal tumours in patients presenting to an academic hospital in South Africa
Creator Robertson, Barbara M. Chinnery, Galya E. Locketz, Michael L. Parker, Michelle Vorster, Alvera A. Ramesar, Raj Panieri, Eugenio Hunter, Alistair J.
Subject Oncology gastrointestinal stromal tumours; Africa; treatment; imatinib; mutations; survival
Description Background: Published information on African patients with gastrointestinal stromal tumours (GISTs) is limited.Aim: The aim of this study was to review patient and tumour characteristics, and treatment, for a cohort of African patients and compare findings to studies from other centres.Setting: Groote Schuur Hospital, South Africa.Methods: Data were collected on all patients referred to Groote Schuur Hospital (GSH) during the period October 2003 to November 2019, including demographics, tumour characteristics and treatment outcomes.Results: There were 124 patients in total. There was a slight male predominance (55.6%) and the median age was 56 years. The most common primary tumour sites were the stomach (66.2%) and small bowel (21.8%) with a median primary tumour diameter of 95.5 mm. Mutational analysis was conducted for 39 patients with 66.7% of these patients having mutations in KIT exon 11. The primary tumour was resected in 72 patients, with 48.6% having high-risk tumours according to the National Institutes of Health (NIH) risk assessment. The 10-year overall survival (OS) values for patients by risk group were 83% (very low and low risk), 73% (intermediate risk) and 66% (high risk). The disease control rate for patients treated with imatinib was 84.6%. The median progression-free survival (PFS) for patients treated with imatinib for palliation was 23 months with OS of 31 months.Conclusion: In contrast to patients from other centres, our patients were younger and had larger tumours.Contribution: The distribution of primary tumour site, mutational analysis and response to imatinib was consistent with the literature.
Publisher AOSIS
Contributor University of Cape Town, Novartis
Date 2023-06-13
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Quantitative research
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajo.v7i0.265
Source South African Journal of Oncology; Vol 7 (2023); 9 pages 2523-0646 2518-8704
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
Coverage Africa, South Africa 2003-2019 Gastrointestinal stromal tumour patients
Rights Copyright (c) 2023 Barbara M. Robertson, Galya E. Chinnery, Michael L. Locketz, Michelle Parker, Alvera A. Vorster, Raj Ramesar, Eugenio Panieri, Alistair J. Hunter